Pemphigus Vulgaris - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pemphigus Vulgaris - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pemphigus Vulgaris - Pipeline Review, H1 2015', provides an overview of the Pemphigus Vulgaris's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pemphigus Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pemphigus Vulgaris and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pemphigus Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pemphigus Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pemphigus Vulgaris Overview 6
Therapeutics Development 7
Pipeline Products for Pemphigus Vulgaris - Overview 7
Pipeline Products for Pemphigus Vulgaris - Comparative Analysis 8
Pemphigus Vulgaris - Therapeutics under Development by Companies 9
Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes 10
Pemphigus Vulgaris - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Pemphigus Vulgaris - Products under Development by Companies 15
Pemphigus Vulgaris - Products under Investigation by Universities/Institutes 16
Pemphigus Vulgaris - Companies Involved in Therapeutics Development 17
Biogen, Inc. 17
Genmab A/S 18
HanAll Biopharma Co., Ltd. 19
Immunomedics, Inc. 20
Novartis AG 21
Pemphigus Vulgaris - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
DP-C006 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
HL-161 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ofatumumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
rituximab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
T-Cell Therapy for Pemphigus Vulgaris - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VAY-736 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
veltuzumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Pemphigus Vulgaris - Recent Pipeline Updates 48
Pemphigus Vulgaris - Dormant Projects 55
Pemphigus Vulgaris - Product Development Milestones 56
Featured News & Press Releases 56
Oct 07, 2014: Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris 56
Jul 04, 2013: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H1 2015 7
Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Pemphigus Vulgaris - Pipeline by Biogen, Inc., H1 2015 17
Pemphigus Vulgaris - Pipeline by Genmab A/S, H1 2015 18
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 19
Pemphigus Vulgaris - Pipeline by Immunomedics, Inc., H1 2015 20
Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Pemphigus Vulgaris Therapeutics - Recent Pipeline Updates, H1 2015 48
Pemphigus Vulgaris - Dormant Projects, H1 2015 55